GLP1 Analogues and the Risk of Osteoarthritis

Sponsor
Beni-Suef University
Study ID
NCT07360457
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GLP-1 analog — DRUG
    glucagon like peptide analogues
  • SGLT2 inhibitor — DRUG
    sodium glucose transporter-2 inhibitors
  • Antidiabetic — DRUG
    Standard of care

Study Details

Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes.

Key Dates

First listed
Jan 22, 2026
Start date
Feb 1, 2026
Status verified
Jan 2026
Primary completion
Dec 1, 2026
Completion
Mar 1, 2027

Study Design

Enrollment
390 participants (estimated)

Arms

  • Arm: SGLT2 Group
    T2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care
  • Arm: GLP1 Group
    T2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care
  • Arm: Control group
    T2DM patients receiving only standard of care

Primary Outcome Measure

WOMAC score [ Time Frame: at Day 1 ]

Central Contacts

Find similar trials

Nationwide
Osteoarthritis (other) trialsOrthopedics trialsMusculoskeletal disorders trials

Related Studies